Invention Grant
- Patent Title: 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions
-
Application No.: US16494650Application Date: 2018-03-19
-
Publication No.: US11028087B2Publication Date: 2021-06-08
- Inventor: Tomas Gucky , Eva Reznickova , Radek Jorda , Vladimir Krystof , Miroslav Strnad , Tereza Radosova Muchova , Vladimir Divoky
- Applicant: UNIVERZITA PALACKEHO V OLOMOUCI
- Applicant Address: CZ Olomouc
- Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
- Current Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
- Current Assignee Address: CZ Olomouc
- Agency: Nortaro, Michalos & Zaccaria P.C.
- Priority: CZCZ2017-157 20170320
- International Application: PCT/CZ2018/050010 WO 20180319
- International Announcement: WO2018/171819 WO 20180927
- Main IPC: C07D473/34
- IPC: C07D473/34 ; C07D491/10 ; C07D487/10 ; A61P35/00
Abstract:
The present invention relates to novel 2,6-disubstituted-9-cyclopentyl-9H-purines of general formula I, capable of inhibiting the activity of kinases such as FLT3, CDKs and PDGFRs in cancer and other related proliferative diseases. The invention further includes pharmaceutical compositions containing the 2,6-disubstituted-9-cyclopentyl-9H-purines. Compounds of the present invention can be used as active ingredients of a pharmaceutical compositions for treating acute myeloid leukemia (AML).
Public/Granted literature
- US20200087306A1 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS Public/Granted day:2020-03-19
Information query
